Veru Inc

The premature ejaculation treatment market is projected to grow by USD 1.46 billion from 2024-2028, driven by high efficacy of off-label drugs and nanotechnology advancements. Key players include A. Menarini, Absorption Pharmaceuticals, Alembic Pharmaceuticals, and others. Challenges include side effects and pandemic-related access issues, with AI and telemedicine offering potential solutions.

Many biotechs that rose during the pandemic have faced challenges as their COVID-19 candidates faltered. CureVac, after its mRNA vaccine's low efficacy, restructured and partnered with GSK. Novavax, despite FDA approval, struggled with uptake and faced a clinical hold on its flu/COVID shot. Inovio Pharmaceuticals, once a frontrunner with DNA-based tech, faced controversy and delayed its FDA application. Veru's antiviral sabizabulin was denied EUA and now focuses on GLP-1 related treatments.

Veru Inc. will present at ObesityWeek on November 5, 2024, discussing enobosarm's potential to optimize weight loss. The Phase 2b clinical trial evaluates enobosarm's safety and efficacy in preserving muscle and augmenting fat loss in sarcopenic obese patients. Topline results are expected in January 2025, with extension study results in Q2 2025.